OncLive TV

Thomas A. Neville, PhD, CEO of Soar Biodynamics in Incline Village, Nevada, discusses PSA growth rate.

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the conclusions of the RTOG 0436 trial, a phase III trial of cisplatin, paclitaxel, and radiation with or without cetuximab in the non-operative treatment of esophageal cancer.

David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective angiopoietin-2 inhibitor MEDI3617 alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.

Bernardo L. Rapoport, MD, chief medical oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa, discusses the utility of rolapitant for preventing chemotherapy-induced nausea and vomiting (CINV).

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses recent advances in liver-directed therapies in colorectal cancer (CRC).

Judd W. Moul, MD, director, Duke Prostate Center, James H. Semans, MD, Professor of Surgery, Duke University Medical Center, discusses the 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix

Dirk Arnold, MD, director, Department of Medical Oncology, Tumour Biology Centre, Freiburg, Germany, discusses a phase III trial looking at options for maintenance therapy for metastatic colorectal cancer (mCRC).

Abraham Chachoua, MD, The Jay and Isabel Fine Associate Professor of Oncology, NYU Langone Medical Center, associate director, Cancer Services, Perlmutter Cancer Center at NYU Langone, discusses ongoing clinical trials at NYU that are evaluating immunotherapy in patients with lung cancer.

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses the development of AZD9291 for lung cancer.

Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.

Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses the next steps for research into radioimmunotherapy.

Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the efficacy of CO-1686 for the treatment of non-small cell lung cancer.

Edith A. Perez, MD, discusses a genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.

Markus Renschler, MD, vice president, global head, Hematology Oncology Medical Affairs at Celgene, discusses updated results of the MPACT study, which examined nab-paclitaxel plus gemcitabine vs gemcitabine for patients with metastatic pancreatic cancer.

Julie R. Gralow, MD, director, Breast Medical Oncology, Seattle Cancer Care Alliance, clinical research division, member, Fred Hutchinson Cancer Care Center, professor, Medical Oncology Division, University of Washington School of Medicine, discusses toxicities observed in the SWOG S0307 trial, which examined bisphosphonates as adjuvant therapy in primary breast cancer.

Jyoti D. Patel, MD, discusses a phase II trial that looked at olaparib in combination with cediranib versus olaparib alone in recurrent platinum-sensitive ovarian cancer.

Kenneth R. Carson, MD, assistant professor, Division of Oncology, Washington University, discusses mogamulizumab as a potential treatment for patients with relapsed or refractory cutaneous T cell lymphoma (CTCL).

Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer.

Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of improved and complete enrichment co-amplification at lower denaturation temperature method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of patients with non-small cell lung cancer (NSCLC).

Charles M. Perou, PhD, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting that analyzed gene expression signatures in patients with HER2-positive breast cancer treated with weekly paclitaxel and trastuzumab with or without lapatinib.

Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men's treatment decisions after seeing a raise in their PSA levels.

Bilal Piperdi, MD, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked at RICTOR amplification to define a subset of patients with lung cancer.

Andrew Kennedy, MD, physician-in-chief, Radiation Oncology, Sarah Cannon, director, Radiation Oncology Research, Sarah Cannon Research Institute, discusses the utilization of radioactive microspheres.

Congresswoman Renee Ellmers (R-NC-02), U.S. House of Representatives, discusses the importance of the Cancer Patient Protection Act of 2013 (H.R. 1416).

Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer(mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.

Mario Sznol, MD, professor, Internal Medicine, Yale Cancer Center, discusses a phase I trial that examined the combination of nivolumab and ipilimumab for the treatment of advanced melanoma.

Catherine M. Diefenbach, MD, assistant professor, medicine (hematology and medical oncology), Perlmutter Cancer Center at NYU Langone, explains antibody drug conjugates (ADCs)